|
1.
|
Ohshima H: Five cases with mesothelioma
living near a now-defunct asbestos cement plant in Amagasaki city.
Mainichi Newspaper (in Japanese). 1June 29–2005.
|
|
2.
|
Robinson BW and Lake RA: Advances in
malignant mesothelioma. N Engl J Med. 353:1591–1603. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Ray M and Kindler HL: Malignant pleural
mesothelioma: an update on biomarkers and treatment. Chest.
136:888–896. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Shi HZ, Liang QL, Jiang J, Qin XJ and Yang
HB: Diagnostic value of carcinoembryonic antigen in malignant
pleural effusion: a meta-analysis. Respirology. 13:518–527. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Liang QL, Shi HZ, Qin XJ, Liang XD, Jiang
J and Yang HB: Diagnostic accuracy of tumour markers for malignant
pleural effusion: a meta-analysis. Thorax. 63:35–41. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Aoe K, Hiraki A, Maeda T, et al: Soluble
receptor-binding cancer antigen expressed on SiSo cells in pleural
fluid: a potential diagnostic marker for malignant pleural
effusion. Chest. 126:1195–1197. 2004. View Article : Google Scholar
|
|
7.
|
Rump A, Morikawa Y, Tanaka M, et al:
Binding of ovarian cancer antigen CA125/MUC16 to mesothelin
mediates cell adhesion. J Biol Chem. 279:9190–9198. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Chang K, Pai LH, Pass H, et al: Monoclonal
antibody K1 reacts with epithelial mesothelioma but not with lung
adenocarcinoma. Am J Surg Pathol. 16:259–268. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Chang K and Pastan I: Molecular cloning of
mesothelin, a differentiation antigen present on mesothelium,
mesotheliomas and ovarian cancers. Proc Natl Acad Sci USA.
93:136–140. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Ordonez NG: Value of mesothelin
immunostaining in the diagnosis of mesothelioma. Mod Pathol.
16:192–197. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Ordonez NG: The immunohistochemical
diagnosis of mesothelioma: a comparative study of epithelioid
mesothelioma and lung adenocarcinoma. Am J Surg Pathol.
27:1031–1051. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Scholler N, Fu N, Yang Y, et al: Soluble
member(s) of the mesothelin/megakaryocyte potentiating factor
family are detectable in sera from patients with ovarian carcinoma.
Proc Natl Acad Sci USA. 96:11531–11536. 1999. View Article : Google Scholar
|
|
13.
|
Frierson HF Jr, Moskaluk CA, Powell SM, et
al: Large-scale molecular and tissue microarray analysis of
mesothelin expression in common human carcinomas. Hum Pathol.
34:605–609. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Bhattacharjee A, Richards WG, Staunton J,
et al: Classification of human lung carcinomas by mRNA expression
profiling reveals distinct adenocarcinoma subclasses. Proc Natl
Acad Sci USA. 98:13790–13795. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Hornick JL, Lauwers GY and Odze RD:
Immunohistochemistry can help distinguish metastatic pancreatic
adenocarcinomas from bile duct adenomas and hamartomas of the
liver. Am J Surg Pathol. 29:381–389. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Watanabe H, Okada G, Ohtsubo K, et al:
Expression of mesothelin mRNA in pure pancreatic juice from
patients with pancreatic carcinoma, intraductal papillary mucinous
neoplasm of the pancreas and chronic pancreatitis. Pancreas.
30:349–354. 2005. View Article : Google Scholar
|
|
17.
|
Hassan R, Bera T and Pastan I: Mesothelin:
a new target for immunotherapy. Clin Cancer Res. 10:3937–3942.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Robinson BW, Creaney J, Lake R, et al:
Mesothelin-family proteins and diagnosis of mesothelioma. Lancet.
362:1612–1616. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Cristaudo A, Foddis R, Vivaldi A, et al:
Clinical significance of serum mesothelin in patients with
mesothelioma and lung cancer. Clin Cancer Res. 13:5076–5081. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Schneider J, Hoffmann H, Dienemann H,
Herth FJ, Meister M and Muley T: Diagnostic and prognostic value of
soluble mesothelin-related proteins in patients with malignant
pleural mesothelioma in comparison with benign asbestosis and lung
cancer. J Thorac Oncol. 3:1317–1324. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Scherpereel A, Grigoriu B, Conti M, et al:
Soluble mesothelin-related peptides in the diagnosis of malignant
pleural mesothelioma. Am J Respir Crit Care Med. 173:1155–1160.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Pass HI, Wali A, Tang N, et al: Soluble
mesothelin-related peptide level elevation in mesothelioma serum
and pleural effusions. Ann Thorac Surg. 85:265–272. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Rusch VW: A proposed new international TNM
staging system for malignant pleural mesothelioma from the
International Mesothelioma Interest Group. Lung Cancer. 14:1–12.
1996. View Article : Google Scholar
|
|
24.
|
Histological Typing of Lung and Pleural
Tumors. World Health Organization; Geneva: 1999
|
|
25.
|
Mountain CF: Revisions in the
International System for staging lung cancer. Chest. 111:1710–1717.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Kohyama N and Suzuki Y: Analysis of
asbestos fibers in lung parenchyma, pleural plaques and
mesothelioma tissues of North American insulation workers. Ann NY
Acad Sci. 643:27–52. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Diagnosis and initial management of
nonmalignant diseases related to asbestos. Am J Respir Crit Care
Med. 170:691–715. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Raviglione MC and Luelmo F: Update on the
global epidemiology of tuberculosis. Curr Issues Public Health.
2:192–197. 1996.PubMed/NCBI
|
|
29.
|
Hiraki A, Aoe K, Eda R, et al: Comparison
of six biological markers for the diagnosis of tuberculous
pleuritis. Chest. 125:987–989. 2004. View Article : Google Scholar : PubMed/NCBI
|
